As of July 24, 2012 - protocols do open and close daily.
Please check with your physician for additional protocols and/or information.
1. S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs. Depot Octreotide + Bevacizumab in Advanced Poor Prognosis Carcinoid Patients
The purpose of this study is to compare the effects, good and/or bad, of octreotide plus bevacizumab with octreotide plus interferon on you and your carcinoid tumor to find out which is better. In this study, you will get either the bevacizumab or the interferon. You will not get both. Interferon is considered an accepted treatment for carcinoid tumors. Octreotide is an accepted treatment for carcinoid tumor and is a standard treatment for carcinoid syndrome. The combination of octreotide and interferon is considered a standard option even for patients who have progressed on octreotide alone. Bevacizumab is considered experimental for treating patients with carcinoid tumors.
For more information on this protocol or any other research, please contact your physician or our clinical research coordinator, Jessica Gerlach, CCRP at 845-333-1133